The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. topic
Also known as
- Add other possible names for this topic
| Author |
| Editor |
| Date written |
| Copyright date |
| Date of first publication |
| Subjects |
| Original language |
| School or Movement |
| Part of series |
| Journal publication |
|
journal
|
volume
|
issue number
|
issue date
|
pages
|
|---|---|---|---|---|
|
|
|
|
|
| DOI |
| Acknowledged people |
| Financial support provided by |
| Keyword |
| Works cited |
| Cited in |
With the exception of Wikipedia summaries and some images the
content on this page is typically distributed under
the Creative Commons
Attribution license or Public Domain.
| Gallery | add |
There are no images for this topic yet.
Edit Weblinks
There are no weblinks for this topic yet.
Recent Discussions about The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.
There are no conversations on this topic. Would you like to start one?
Start the Discussion »